Medtronic Xomed

9 dispositifs dans la base de données

  • Modèle / numéro de série
    8003097, 8003098, 8003099, 8004000, 8004001 , 8004002, 8004003, 8004004, 8004005, 8004006, 8004007, 8004008, 8004009, 8004050, 8004051, 8004052, 8004053, 8004054, 8004055, 8004056, 8004057 | all
  • Description du dispositif
    MD: Cottonoid pad
  • Modèle / numéro de série
    300501, 300503, 300505, 300506, 300507, 300509, 300510, 300514, 300515, 400611 | all
  • Description du dispositif
    MD: Cottonoid pad
  • Modèle / numéro de série
    BNP2001, BNP2002, CNP2001, CNP2002, FTP1001, MNP1001, PSP1000, PSP1001, PSP1002, FTP2001, MNP2001, PSP2000, PSP2001, PSP2002
  • Description du dispositif
    MD: Single-use Stimulator Probes
  • Modèle / numéro de série
    NWCPUE4, NCCPUE4, NCCPU, NWCPU
  • Description du dispositif
    MD: Nerve-locating system, line-powered
  • Modèle / numéro de série
    8229306, 8229307, 8229308, 8229506, 8229507, 8229508 | All
  • Description du dispositif
    MD: Electromyographic needle electrode, single-use
4 en plus

24 fabricants avec un nom similaire

En savoir plus sur les données ici

  • Société-mère du fabricant (2017)
  • Commentaire du fabricant
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Source
    NZMMDSA
  • Société-mère du fabricant (2017)
  • Commentaire du fabricant
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Source
    NZMMDSA
  • Société-mère du fabricant (2017)
  • Commentaire du fabricant
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Source
    MSHM
  • Adresse du fabricant
    Medtronic Xomed, Inc., 6743 Southpoint Dr N, Jacksonville FL 32216-6218
  • Société-mère du fabricant (2017)
  • Commentaire du fabricant
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Source
    USFDA
19 en plus